Experts opinion and technical assessment allows the selection of drug related problems to be targeted by a CDSS in pediatrics

Selection of clinical rules for the screening of high-risk situations in paediatric medicine

Christian Skalafouris^{1,2}, Léa Gérard^{1,2}, Thomas Rudolf von Rohr^{1,2}, Pascal Bonnabry^{1,2}, Caroline Fonzo-Christe¹

- ¹ Geneva University Hospital, Pharmacy Department, Geneva, Switzerland
- ² University of Geneva, Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), School of pharmaceutical sciences

Objectives

- Develop a selecting method for clinical rules (CR) dedicated to prevent critical drug related problems (DRP) via our clinical decision support system (CDSS)
- Draw up a list of CR adapted to the pediatric department

Conclusion

- Selection criteria for CR took into account
 - Experts opinion regarding DRP potentiel clinical impact and relevance
- > The feasibility to implement CR in PharmaCheck
- 24 Clinical rules were selected, 8 concerned all pediatric specialities and shoud be implemented in priority for better efficiency

PharmaCheck

is a CDSS for the screening of high-risk situations with CR involving drug prescriptions, lab values, vital signs and medical problems

CR were scored by the pharmacist in charge of PharmaCheck for technical feasibility, by the expert panel for relevance and criticality

Technical feasibility scale		Clinical relevance scale	
Score	Definition	Score	Definition
0	No feasible	0	No relevant
33.3	Hardly feasible	33.3	CR is relevant if modified
66.6	Easily feasible	66.6	Relevant
100	Very easily feasible	100	Very relevant

15 to 25 **Extreme** High 8 to 14 4 to 7 **Moderate** 1 to 3 Low

Probability of occurrence scale (Score = P)			
Score	Definition		
1	Rare		
2	Unlikely		
3	Possible		
4	Likely		
5	Almost certain		

Criticality = PxS Severity of DRP scale (score = S)Score **Definition** Negligible Minor 3 Moderate Major Catastrophic

Identification of clinical rules potentially relevant for pediatrics

with a literature review: 56 CR potentially relevant for children were selected and presented to 14 senior physicians (experts) in 8 pediatric specialties

Inclusion of pediatric medical specialties

according to the 2 computerized physician order entries used ∠in Geneva University Hospital

Group A: general pediatrics, oncology, pneumology, gastroenterology/hepatology, surgery, cardiology;

Group B: intensive care, neonatalogy



Criticality score ≥ 8 Relevance score = 100 Feasibility score ≥ 66.6 CR concerning only 1 pediatric specialty (assessed by 1 expert)

> Criticality score ≥ 15 Relevance score = 100 Feasibility score ≥ 66.6

Drug-drug interaction

Prescription of CYP3A4 substrate with a

strong inducer or inhibitor Co-prescription of ≥ 3 analgesic or sedative drugs Co-prescription of ≥ 2 NSAIDs Co-prescription of a macrolide with ciclosporin or tacrolimus Co-prescription of methotrexate and trimethoprim Co-prescription of immunosuppressive therapy over/under-dosed (blood level) with a strong CYP3A4 inducer or inhibitor Co-prescription of parenteral calcium with digoxine

Co-prescription of aminoglycoside with

another ototoxic medication

Co-prescription of ≥ 2 nephrotoxic

medications

Co-prescription of ≥ 2 drugs inducing QT-

prolongation

Medication with abnormal lab value

Parenteral potassium chloride with hyperkaliemia Vancomycin dose not adjusted to renal function Aminoglycosides prescription with supratherapeutic blood levels Furosemide prescription with hypokaliemia, hyponatremia or hypovolemia Heparin prescription with thrombopenia Insulin prescription with hypoglycemia Low molecular weight heparin prescription

with severe or terminal renal impairement

Inappropriate administration mode

Clinical rule

scoring

Clinical rules

selection

criteria

Methotrexate inappropriate frequency of administration

Vancomycine inappropriate length of administration

Peripheral venous infusion of potassium chloride at a concentration greater than 40 mmol/l

Medication contraindicated or to use with caution

Dose confusion between non-liposomal and liposomal amphotericine-B

Prescription of a nephrotoxic medication for \geq 3 days

Paracetamol dose greater than maximum authorized daily-dose/unique dose

Medication omission

Opioid prescription for more > 48h without laxative medication

C _ J CR common to all specialties in group A and group B

CR specific for group A

CR specific for group B

24 clinical rules were selected after assessment of their criticality, their relevance and their technical feasibility







